Inhibiting Hedgehog/GLI signaling and downstream KIT expression, as well as other ATO targets, represents a novel and clinically potentially realizable approach to disrupting GIST dependence on KIT signaling for survival. Here, GLI1 is linked to gastrointestinal stromal tumor.